Reata $RETA shares took a nosedive Wednesday after the biotech ... trial unveiled Wednesday at the virtual San Antonio Breast Cancer Symposium.
News
- News briefing: FDA requests new trial for Reata's Friedreich's ataxia program; J&J's Tremfya picks ...
- After 5 quiet years, a former Scripps spinout raises $200M and announces plans to try again at an ...
The first time San Diego biotech Ambrx tried to go public in 2014, they failed and the company's board switched to a radically different strategy: They ...
- Overnight fortunes are being made in biotech these days — and it's both encouraging and more ...
The current biotech mania also presents a prime opportunity to illustrate how ... As long as these massive stakes are up for grabs, biotech will continue to ... unveiled Wednesday at the virtual San Antonio Breast Cancer Symposium.
- News briefing: AbbVie partner Teneobio expands tech license with CAR-T player Poseida; Argenx ...
The Dutch biotech announced it has purchased a PRV from Bayer for $98 million to advance review of a future program for its FcRn antagonist ...
- SANS Announces 2020 Difference Makers Awards Winners
"The Difference Makers range from individual contributors to teams of people, from a Secretary of State to a Biotechnology Threat Focus team to a ...